908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, is showcasing the use of its high-pressure mass spectrometry and microfluidics separation technologies in twelve presentations at the 70^th American Society for Mass Spectrometry (ASMS) Conference June 5-9 in Minneapolis. The presentations, which include one oral and eleven posters, highlight technology to accelerate drug development workflows, and include collaborators such as Boehringer Ingelheim, Genentech, University of Washington, Fudan University, and Dana-Farber Cancer Institute.

Mass Spec for the Masses

908 Devices is democratizing mass spec with its handheld and desktop devices that are simple to operate, provide answers in minutes and are used at the point of need, making mass spec more accessible to more scientists.

The company’s ZipChip^® device leverages microfluidic-based Capillary Electrophoresis (CE) and electrospray ionization technology to minimize sample prep burden, perform high-resolution separations and directly introduce samples into a Thermo Fisher Scientific, Bruker or Sciex mass spectrometer.

The majority of ASMS presentations by 908 Devices and its collaborators note the use of ZipChip in either oligonucleotides, metabolomics, or proteomics applications—all areas of increasing importance in the development of new therapeutics. The ZipChip Oligos assay kit provides a fast and simple means to obtain high-resolution separation and mass spec data from a wide range of oligonucleotides, with minimal sample prep and without the need of harsh ion pairing reagents.

In the area of proteomics, the company will highlight, in a key oral presentation, updates to its microfluidic prototype chip developments that couple solid phase extraction to accommodate larger sample volumes as well as chip increases in speed and sensitivity. Scientists from the Dana-Farber Cancer Institute will present their research utilizing the prototype chips for ‘warp-speed profiling’ of deubiquitinase small molecule inhibitors.

In addition, 908 Devices will present two posters on quantitation of amino acids in cell culture media using its REBEL™ desktop device, a first-of-its-kind fresh and spent media analyzer that enables biopharma researchers to accelerate process development cycles and maximize bioreactor utilization by running media analysis at-line.

Exhibit and Presentations at ASMS

908 Devices will exhibit its handheld and desktop devices in booth #409 at ASMS, and here is a list of ASMS presentations by 908 Devices and collaborators:

Oral Presentation – Wednesday, June 8

• Pushing the Boundaries of Speed and Sensitivity in Proteomics: Coupling SPE-enabled Microfluidic Capillary Electrophoresis with Ultrafast Tandem Mass Spectrometry
  
  Collaboration: 908 Devices, Thermo Fisher Scientific, University of Washington

Poster Presentations

Monday, June 6

• A Broad Application of Migration Time Indexing and Metabolite Libraries to Evaluate Quantitative Coverage in Microchip CE-MS Metabolomics
  
  908 Devices
  
  

• Dynamic Range Optimization for Amino Acid Quantitation with an Integrated CE-MS Analyzer
  
  908 Devices

Tuesday, June 7

• Glycosylation Profiling of Cetuximab Subunits with CZE-MS
  
  Collaboration: 908 Devices, Bruker

Wednesday, June 8

• Capillary Electrophoresis Mass Spectrometry (CEMS) of Oligonucleotides using a 908 Devices ZipChip
  
  Collaboration: 908 Devices, Boehringer Ingelheim
  
  

• Microchip CE-MS Analysis of Sialylated N-glycan Linkage Isomers
  
  Collaboration: 908 Devices, Fudan University
  
  

• A Sensitive and High-Throughput Assay for Analyzing Peptide Exchanged MHCI by High Resolution Native CZE-MS
  
  Collaboration: 908 Devices, Genentech
  
  

• Combining µSPE Chip-based CE with PRM-LIVE and Dynamic Targeting Scheduling for Warp-speed Selectivity Profiling of Deubiquitinase Small Molecule Inhibitors
  
  Collaboration: 908 Devices, Dana-Farber, Bruker
  
  

• Using CE-HPMS for Accelerated Process Development of a mAb-expressing Cell Line
  
  Collaboration: 908 Devices, CPI

Thursday, June 9

• Rapid Characterization of Oligonucleotides and Related Impurities using Microchip CE-MS Without Ion-pairing Reagents
  
  Collaboration: 908 Devices, Thermo Fisher Scientific
  
  

• Multi-level Expeditious Characterization of Adeno-associated Virus (AAV) Capsid Proteins Using ZipChip Microfluidic CE Coupled with HRMS
  
  Collaboration: 908 Devices, Thermo Fisher Scientific
  
  

• Bottom-up Analysis of Progressively Larger RNAs by CZE-MS and CZE-MS/MS
  
  Collaboration: 908 Devices, University of Connecticut, Bruker

For more information about our ASMS presentations, visit Mass Spec For the Masses - 908 Devices.

About 908 Devices

908 Devices Inc. (Nasdaq: MASS) is democratizing laboratory mass spectrometry with its simple handheld and desktop devices, addressing critical-to-life applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma / biopharma, forensics and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic separations, software automation and machine learning.

Forward Looking Statements

This press release includes “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the expected uses and capabilities of the Company’s products. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under “Risk Factors” and elsewhere in the Company’s filings with the Securities and Exchange Commission which are available on the SEC's website at www.sec.gov. Additional information will be made available in the Company’s annual and quarterly reports and other filings that it makes from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220602005261/en/